Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Zhejiang Chinese Medical University currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to a single examiner, SHARMA, UMANG, who is the busiest examiner for the portfolio with 1 pending action. The concentration of the portfolio is reflected in the use of 1 distinct art unit and 1 distinct examiner. Practitioners should note that prosecution for this entity is currently localized to this specific examiner and art unit.
Because there is only a solitary pending matter, the busiest examiner handles the entirety of the company's current active workload at the office. This creates a centralized prosecution environment where all outcomes depend on the review of the assigned individual within the designated technical group. The focus on the Biotechnology & Pharmaceuticals sector suggests that the university's patent strategy is currently narrow in scope, targeting a specific technical field through a single administrative channel. This lack of distribution across multiple personnel simplifies the monitoring of the portfolio but increases reliance on the specific tendencies of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHARMA, UMANG | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18657726 | BIOMARKERS FOR SEVERITY OF ISCHEMIC STROKE AND USE THEREOF | SHARMA, UMANG | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18657726 | BIOMARKERS FOR SEVERITY OF ISCHEMIC STROKE AND USE THEREOF | SHARMA, UMANG | 1677 | §101§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Chinese Medical University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Umang Sharma has the most, with 1 of Zhejiang Chinese Medical University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
